Benjamin J Drapkin
Overview
Explore the profile of Benjamin J Drapkin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
806
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peinado P, Stazi M, Ballabio C, Margineanu M, Li Z, Colon C, et al.
Nature
. 2025 Feb;
PMID: 39939778
Elevated or ectopic expression of neuronal receptors promotes tumour progression in many cancer types; neuroendocrine (NE) transformation of adenocarcinomas has also been associated with increased aggressiveness. Whether the defining neuronal...
2.
Chatterjee D, Svoboda R, Huisman D, Drapkin B, Vieira H, Rao C, et al.
Mol Cancer Res
. 2025 Feb;
PMID: 39927878
Small-cell lung cancer (SCLC) has a dismal five-year survival rate of less than 7%, with limited advances in first line treatment over the past four decades. Tumor-initiating cells (TICs) contribute...
3.
Nadeem U, Drapkin B
Cancer Discov
. 2025 Jan;
15(1):8-10.
PMID: 39801239
Small cell lung cancer (SCLC) and pulmonary carcinoid tumors are traditionally seen as unrelated, with SCLC linked to smoking and characterized by biallelic loss of RB1 and TP53 and rapid...
4.
Nguyen A, Nunez C, Tran T, Girard L, Peyton M, Catalan R, et al.
Oncogene
. 2024 Aug;
43(38):2885-2899.
PMID: 39154123
Small cell lung cancer (SCLC) is a recalcitrant cancer of neuroendocrine (NE) origin. Changes in therapeutic approaches against SCLC have been lacking over the decades. Here, we use preclinical models...
5.
Duplaquet L, So K, Ying A, Pal Choudhuri S, Li X, Xu G, et al.
Cancer Cell
. 2024 Jul;
42(8):1352-1369.e13.
PMID: 39029464
Small cell lung cancers (SCLCs) are composed of heterogeneous subtypes marked by lineage-specific transcription factors, including ASCL1, NEUROD1, and POU2F3. POU2F3-positive SCLCs, ∼12% of all cases, are uniquely dependent on...
6.
Chatterjee D, Svoboda R, Huisman D, Drapkin B, Vieira H, Rao C, et al.
bioRxiv
. 2024 Mar;
PMID: 38464216
Statement Of Implication: Genetic manipulation of the molecular scaffold KSR1 in small-cell lung cancer cells reveals its contribution to cisplatin resistance and tumor initiation.
7.
Pal Choudhuri S, Girard L, Lim J, Wise J, Freitas B, Yang D, et al.
Cancer Discov
. 2024 Feb;
14(5):804-827.
PMID: 38386926
Significance: SCLC is initially chemosensitive, but acquired cross-resistance renders this disease refractory to further treatment and ultimately fatal. The genomic drivers of this transformation are unknown. We use a population...
8.
Eglenen-Polat B, Kowash R, Huang H, Siteni S, Zhu M, Chen K, et al.
Nat Commun
. 2024 Jan;
15(1):672.
PMID: 38253555
There are few effective treatments for small cell lung cancer (SCLC) underscoring the need for innovative therapeutic approaches. This study focuses on exploiting telomerase, a critical SCLC dependency as a...
9.
Kim C, Wang X, Liu Z, Hao J, Wang S, Li P, et al.
Sci Adv
. 2024 Jan;
10(3):eadh2579.
PMID: 38241363
Although mutations are not commonly found in small cell lung cancer (SCLC), a substantial fraction of SCLC shows clinically relevant response to PARP inhibitors (PARPis). However, the underlying mechanism(s) of...
10.
Chen H, Drapkin B, Minna J
Cell
. 2024 Jan;
187(1):14-16.
PMID: 38181738
Small cell lung cancer (SCLC) is a recalcitrant malignancy. Conquering it will require deep insight into its biology. In this issue of Cell, Liu and colleagues describe proteomic and phosphoproteomic...